美股異動|諾和諾德盤前繼續上漲4% 此前5日連漲超16%
丹麥製藥商諾和諾德(NVO.US)盤前繼續上漲4%,該股此前連漲5日,區間漲幅達16.3%。消息上,華泰證券認爲,GLP-1已展現較大的市場潛力,而目前海外MNC僅諾和諾德和禮來兩巨頭銷售領先,但尚未形成完整產品矩陣,其他MNC產品仍處於臨牀階段,競爭格局尚未定型,產品空缺較大。諾和諾德日前表示,繼續按三班倒運作多家工廠,從而滿足Wegovy和Ozempic需求。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.